Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Extracellular recordings were obtained from single neurons located in the lateral septum, an area known to receive a vasopressinergic innervation in the rat brain. Approximately half of the neurons tested responded to 8-L-arginine vasopressin (AVP) by a marked increase in firing rate at concentrations greater than 1 nM. The effect of vasopressin was blocked by synthetic structural analogues possessing antagonistic properties on peripheral vasopressin and
oxytocin
receptors.
Oxytocin
was much less potent than vasopressin in firing septal neurons, and a selective oxytocic agonist was totally ineffective. The action of vasopressin on neuronal firing was mimicked by the vasopressor agonist [2-phenylalanine,8-
ornithine
]vasotocin but not by the selective antidiuretic agonist 1-deamino[8-D-arginine]vasopressin. In a parallel study, sites that bind [3H]AVP at low concentration (1.5 nM) were found by in vitro autoradiography in the lateral septum. Adjacent sections were also incubated with 1.5 mM [3H]AVP and, in addition, with 100 nM [2-phenylalanine,8-
ornithine
]vasotocin or 1-deamino[8-D-arginine]vasopressin--i.e., the same compounds as those used for the electrophysiological study. Results showed that the vasopressor agonist, but not the antidiuretic agonist, displaced [3H]AVP, thus indicating that the vasopressin binding sites detected by autoradiography in the septum were V1 (vasopressor type) rather than V2 (antidiuretic type) receptors. Based on the electrophysiological evidence, we conclude that these receptors, when occupied, lead to increased firing of lateral septal neurons.
...
PMID:Electrophysiological and autoradiographical evidence of V1 vasopressin receptors in the lateral septum of the rat brain. 295 62
The neurohypophysial hormones
oxytocin
(OT) and vasopressin (VP) are involved in the regulation of the contractility of the male genital tract in several animal species. We investigated the presence of specific binding sites for [3H]OT and [3H]arginine VP (AVP) in membranes prepared from tunica albuginea, epididymis, and vas deferens from prepubertal pigs 2-16 weeks of age. Membranes were incubated with [3H]OT and [3H]AVP in the presence or absence of the corresponding unlabeled peptides. Binding equilibrium was reached in 60 min at 22 C. Millimolar concentrations of Mg2+ increased the specific binding of both ligands. Analysis of families of self- and cross-displacement curves using the computer program LIGAND clearly demonstrated that two classes of binding sites were present in all tissues investigated. The first class of sites, designated the OT site, shows high affinity for OT, AVP, lysine vasopressin, arginine vasotocin, the selective OT agonists [Thr4,Gly7]OT and [Asu1,6]OT, and the OT antagonists derived from
ornithine
vasotocin (OVT), namely d(CH2)5Tyr(Et)OVT and dEt2OVT. The second class of sites, designated the VP site, shows high affinity for AVP, lysine vasopressin, arginine vasotocin, and the selective V1 antagonist d(CH2)5Tyr(Me)AVP. The V2 agonist [1-deamino,4-valine]8-D-AVP shows low affinity for both sites. Isotocin, desglycinamide [Arg-8]AVP and tocinoic acid were ineffective in displacing [3H]AVP or [3H]OT. The highest density of OT receptors was found in tunica albuginea and epididymis, whereas the highest density of AVP receptors was found in vas deferens. Adenylate cyclase was not activated in any of the tissues studied by concentrations of AVP or OT up to 100-fold greater than their Kd values. This is the first demonstration and pharmacological characterization of specific OT and V1 VP receptors in the tunica albuginea, epididymis, and vas deferens. The recent demonstration of high local concentration of neurohypophysial hormones in the gonads of several mammals support a physiological role of these OT and VP receptors in regulation of the motility of the male genital tract.
...
PMID:Identification and characterization of two classes of receptors for oxytocin and vasopressin in porcine tunica albuginea, epididymis, and vas deferens. 302 94
The present study was designed to evaluate the possible physiological role of
oxytocin
(
OXY
) on PRL release by examining the effect of administration of potent pharmacological antagonists of
OXY
on the stimulation of PRL secretion observed in vitro from anterior pituitary (AP) cells in response to
OXY
administration or in a number of in vivo paradigms.
OXY
caused a dose-related increase in PRL release from dispersed AP cells and short term AP cell cultures which was blocked by administration of the
OXY
antagonists [1-deaminopenicillamine, 2-O-methyltyrosine, 8-
ornithine
]vasotocin (dPOMeOVT) or [1-(beta-mercapto-beta,beta-cyclopentamethylene propanoic acid)2-O-methyltyrosine, 8-
ornithine
]vasotocin (MPOMeOVT), respectively. The antagonists were given in vivo in a dose that completely blocked suckling-induced milk let-down for up to 90 min. Injection of the antagonists did not alter the 5-hydroxytryptophan-induced increase in plasma PRL or the increase associated with acute ether stress or acute suckling stimuli, suggesting that
OXY
is not a major component involved in the neuroendocrine mechanisms responsible for those particular increases. On the other hand, iv administration of dPOMeOVT or MPOMeOVT prevented the increase in plasma PRL normally observed on the afternoon of proestrus in the cycling female rat. The characteristic surge of LH was also blocked by high doses of these antagonists. These data demonstrate that PRL secretion undergoes a differential regulation, in that
OXY
appears to play a major role in regulating the increase in plasma PRL observed on the afternoon of proestrus, but apparently provides little, if any, contribution toward the neuroendocrine regulation of the increases in PRL associated with 5-hydroxytryptophan administration, acute ether stress stimulus, or acute suckling stimulus. The data also suggest that
OXY
receptors located in the AP that are involved in the
OXY
-induced increase in PRL release may be similar to those
OXY
receptors located in mammary and uterine tissue, since specific biological effects of
OXY
in those tissues are effectively blocked by the
OXY
antagonists dPOMeOVT and MPOMeOVT. A possible role of
OXY
neurons in the neural mechanisms triggering the LH surge during proestrus is also suggested.
...
PMID:Role of oxytocin on prolactin secretion during proestrus and in different physiological or pharmacological paradigms. 333 12
The nature of the activity of vasopressin that is responsible for the inhibition of renin secretion was studied in normally hydrated conscious dogs using intravenous infusions of vasopressin and analogues of vasopressin with selective antidiuretic and vasoconstrictor activity. Vasopressin (1.0 ng . kg-1 . min-1) increased mean arterial pressure (MAP) from 106 +/- 2 to 115 +/- 3 mmHg (P less than 0.05) and decreased heart rate (HR) from 81 +/- 6 to 56 +/- 5 beats/min (P less than 0.001). Plasma renin activity (PRA) decreased from 4.4 +/- 1.1 to 2.4 +/- 0.8 ng . ml-1 . 3 h-1 (P less than 0.05). A specific antagonist of the vasoconstrictor activity of vasopressin, d(CH2)5MeTyrAVP (10 micrograms/kg), completely blocked the cardiovascular and renin responses to vasopressin. A selective vasoconstrictor agonist, 2-phenylalanine-8-
ornithine
oxytocin
(1.0 ng . kg-1 . min-1), increased MAP from 112 +/- 4 to 128 +/- 6 mmHg (P less than 0.001) and decreased HR from 69 +/- 3 to 47 +/- 4 beats/min (P less than 0.001). PRA decreased from 5.5 +/- 1.1 to 2.7 +/- 0.2 ng . ml-1 X 3 h-1 (P less than 0.001). In contrast, a selective antidiuretic agonist, 1-deamino-8-D-arginine vasopressin (1.0 ng . kg-1 . min-1) did not alter PRA, MAP, or HR. These results demonstrate that the acute inhibition of renin secretion by vasopressin in normally hydrated conscious dogs is due to vasoconstrictor rather than antidiuretic activity.
...
PMID:Role of the vasoconstrictor and antidiuretic activities of vasopressin in inhibition of renin secretion in conscious dogs. 351 May 66
The nature of the activity of vasopressin which is responsible for the inhibition of renin secretion was studied by comparing the effects of vasopressin (AVP) and analogs of AVP in anesthetized water-loaded dogs. Infusion of AVP (1.0 ng/kg/min) increased mean arterial pressure (MAP) and decreased heart rate (HR) and free water clearance (CH2O). Plasma renin activity (PRA) decreased from 11.9 +/- 4.7 to 3.8 +/- 1.7 ng/ml/3 hr (p less than 0.05). A selective antidiuretic agonist, 1-deamino-8-D-arginine vasopressin (1.0 ng/kg/min), which had no effect on MAP or HR but was effective as AVP in decreasing CH2O, decreased PRA from 13.5 +/- 4.6 to 7.0 +/- 2.9 ng/ml/3 hr (p less than 0.05). Infusion of a selective vasoconstrictor agonist, 2-phenylalanine-8-
ornithine
oxytocin
(1.0 ng/kg/min), increased MAP and decreased HR but did not decrease CH2O or PRA. A vasoconstrictor antagonist, d(CH2)5Tyr(Me)AVP (10 micrograms/kg), completely blocked the MAP and HR responses to AVP but did not block the decrease in CH2O or PRA (5.9 +/- 1.8 to 2.9 +/- 1.6 ng/ml/3 hr) (p less than 0.001). Infusion of the 0.45% saline vehicle had no significant effect on MAP, HR, CH2O or PRA. These results indicate that the inhibition of renin secretion by vasopressin in anesthetized water-loaded dogs is due to its antidiuretic activity.
...
PMID:Role of antidiuretic activity in the inhibition of renin secretion by vasopressin in anesthetized dogs. 352 May 11
Recently we reported the discovery of a series of 2-O-alkyltyrosine- (or 2-p-alkylphenylalanine), 4-threonine-, and 8-
ornithine
-substituted analogs of [1-penicillamine]
oxytocin
[( Pen1]OT) which possess prolonged anti-OT activity. In this study, we attempt to improve the potency and the duration of action of this series of OT antagonists by exploring the effects of D-stereoisomer substitution in the 2 position. We compare the in vitro anti-OT potency, expressed in pA2 values, and the duration of in vivo inhibitory action, expressed in recovery t1/2, of [Pen1]OT, [Pen1,Orn8]OT, [Pen1,Thr4]OT, [Pen1,Tyr(OMe)2,Thr4, Orn8]OT, [Pen1, Tyr(OEt)2,Thr4,Orn8]OT, [Pen1,D-Tyr(OEt)2,Thr4,Orn8]OT, [Pen1,Phe2,Thr4]OT, [Pen1,Phe(Me)2,Thr4,Orn8]OT, [Pen1,D-Phe(Me)2,Thr4,Orn8]OT, [Pen1,Phe(Et)2,Thr4,Orn8]OT, and [Pen1,D-Phe(Et)2,Thr4,Orn8]OT. The results show that modifications of the amino acid in position 2 by alkylation of the aromatic ring and use of D-stereoisomerism produce nonparallel effects on the in vitro potency and duration of action of OT antagonists. Time-action curve determinations show that long-acting OT antagonists exhibit delayed peak inhibitory action. Long action is not coupled with high potency in all cases. This dissociation between potency and duration of action gives support to our hypothesis that the potency and duration of action of these peptides may each have different conformational structure requirements.
...
PMID:Long-acting oxytocin antagonists: effects of 2-D-stereoisomer substitution on antagonistic potency and duration of action. 357 33
Endogenous
oxytocin
released into the brain at parturition may stimulate the onset of maternal behaviour. In this study an attempt was made to block spontaneous maternal behaviour following natural delivery in Wistar rats by the injection of an antagonist of
oxytocin
into the cerebral ventricles. The analogue antagonist, d(CH2)5-8-
ornithine
-vasotocin, was administered by injection into a chronically implanted cannula in the right lateral ventricle at hourly intervals, beginning immediately after the expulsion of the first pup. The antagonist did not interfere with the normal progress of parturition or birth-related behaviours. After delivery of the last pup, mothers rested for 40 min in the test cage with the pups having been removed. Four pups and standard nesting material were then presented. Latency to pup carrying and duration of pup manipulation, nest building, and time spent on the nest with the pups, as well as duration of autogrooming and general activity were determined. Saline-injected controls started gathering the pups immediately and usually showed all elements of maternal behaviour within 10 min. Antagonist-treated mothers showed a marked delay in the onset of pup grouping and other maternal behaviours. At the end of 1 h, two out of six mothers had not yet picked up a single infant. Pups left overnight with their mothers were gathered into the nest and suckled, and no long-term effects of the antagonist were evident on retesting. The effectiveness of
oxytocin
antagonist in suppressing the rapid onset of post-partum maternal behaviour supports the hypothesis that centrally released
oxytocin
is involved in this process.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Inhibition of post-partum maternal behaviour in the rat by injecting an oxytocin antagonist into the cerebral ventricles. 381 39
Arginine vasopressin (AVP) is known to produce increases in total peripheral resistance (TPR) and mean arterial pressure (MAP) and decreases in heart rate (HR), cardiac output (CO), and plasma renin activity (PRA). Some recent observations with AVP and synthetic analogues have suggested that under certain conditions, AVP can induce cardiovascular and reninsecretory responses in the opposite directions. To characterize the receptors mediating these responses, the effects of AVP,
oxytocin
, and synthetic neurohypophyseal analogues with specific antidiuretic, vasoconstrictor, or oxytocic activities were studied in conscious dogs. AVP and 2-phenylalanine-8-
ornithine
-
oxytocin
(Phe2Orn8OT, a selective vasoconstrictor agonist) produced similar responses when infused at 10 ng X kg-1 X min-1. That is, TPR and MAP increased, and CO, HR, and PRA decreased. Pretreatment with a selective vasoconstrictor antagonist, [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid) 2-(O-methyl)tyrosine]AVP, abbreviated d(CH2)5Tyr(Me)-AVP (10 micrograms/kg), blocked the actions of Phe2Orn8OT. However, in the presence of d(CH2)5Tyr(Me)AVP, AVP actually decreased TPR and increased CO, HR, and PRA. An analogue with selective antidiuretic activity, 4-valine-8-D-AVP (VDAVP, 10 ng X kg-1 X min-1), produced the same effects as the combination of vasopressin plus d(CH2)5Tyr(Me)AVP. Neither the effects of VDAVP nor of AVP plus antagonist were blocked by propranolol (1 mg/kg). These data indicate that vasopressin, by its antidiuretic activity, produces cardiovascular effects that are opposite to many of those produced by its vasoconstrictor action and that these effects are not dependent on mediation by beta-adrenoceptors.
...
PMID:Hemodynamic effects of neurohypophyseal peptides with antidiuretic activity in dogs. 384 Jun 55
Intracerebroventricular (i.c.v.) infusions of
oxytocin
(
OXY
) induce short-latency maternal behavior in estrogen-primed virgin rats. To investigate if brain
OXY
might have a role in the onset of maternal behavior at parturition, we have used both antisera to
OXY
and an analog antagonist of
OXY
, d(CH2)5-8-
ornithine
-vasotocin, to reduce the activity of endogenous
OXY
in a pregnancy-terminated preparation which yields reliable short-latency maternal behavior. Sprague-Dawley rats with lateral ventricle cannulae were ovariectomized and hysterectomized on day 16 of gestation; maternal behavior was stimulated by a s.c. injection of estradiol benzoate (EB). Effects of the i.c.v. infusion of antisera to
OXY
or of the i.c.v. infusion of d(CH2)5-8-
ornithine
-vasotocin on the latency to respond to pups were tested by presenting pups 48 h after surgery and EB treatment. Behavioral observations were made for the next 5 h and periodically over the next 5 days. Groups receiving either the antisera to
OXY
or the analog antagonist had significantly longer latencies to respond to pups than did control groups. In a separate experiment, i.c.v. infusion of d(CH2)5-8-
ornithine
-vasotocin was shown to have no effect on the performance of maternal behavior in lactating rats 5 days postpartum. These results suggest that
OXY
may have a role in promoting short-latency maternal behavior in steroid-primed female rats, but that it is probably not involved in sustaining this behavior during lactation.
...
PMID:Possible role for endogenous oxytocin in estrogen-facilitated maternal behavior in rats. 401 Aug 91
1. The effect of intramuscular injection of 8-arginine vasotocin, 8-arginine vasopressin, 8-lysine vasopressin,
oxytocin
, 8-
ornithine
oxytocin
and 8-
ornithine
vasopressin on fluid uptake across the skin was studied in the live toad, Bufo melanostictus, bathed either in distilled water or in NaCl solution (0.1 g/100 ml.).2. When the bathing solution was distilled water, 8-arginine vasotocin was the most potent, 0.14 nmole/kg augmenting the rate of fluid uptake by 50%. Compared with it the others had relative potencies of: 8-arginine vasopressin 0.8, 8-lysine vasopressin 0.8 x 10(-3),
oxytocin
0.8 x 10(-3), 8-
ornithine
oxytocin
0.8 x 10(-2), 8-
ornithine
vasopressin < 1.4 x 10(-4).3. When the bathing solution contained 0.1% NaCl, 8-arginine vasotocin was again the most potent, 0.06 nmole/kg augmenting the rate of fluid uptake by 50%. Compared with it the others had relative potencies of: 8-arginine vasopressin 0.3, 8-lysine vasopressin 0.3 x 10(-3),
oxytocin
0.3 x 10(-2), 8-
ornithine
oxytocin
0.8 x 10(-2), 8-
ornithine
vasopressin < 0.6 x 10(-4).4. Dose-response curves for each peptide showed that in the case of 8-arginine vasopressin, 8-lysine vasopressin and 8-
ornithine
vasopressin the augmentation of rate of fluid uptake did not differ in the absence or in the presence of NaCl in the bathing solution; whereas in the case of 8-arginine vasotocin,
oxytocin
, and 8-
ornithine
oxytocin
the augmentation was greater in the presence of sodium chloride.5. Support has been found for the postulate of a binary action of some neurohypophysial peptides on amphibian skin, arginine in position 8 being correlated with hydrosmotic effect, and isoleucine in position 3 with natriferic effect.
...
PMID:Natriferic and hydrosmotic effects of neurohypophysial peptides and their analogues in augmenting fluid uptake by Bufo melanostictus. 567 41
<< Previous
1
2
3
4
5
6
7
Next >>